Valproate Toxicity Questions & Answers

1. Pons S, Gonzva J, Prunet B, Gaillard T, Brisou P, Vest P. Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity. Clin Toxicol (Phila). 2012 Apr. 50(4):268. [QxMD MEDLINE Link].

2. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila). 2006. 44(6-7):803-932. [QxMD MEDLINE Link].

3. Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013 Oct. 46(15):1323-38. [QxMD MEDLINE Link].

4. Graudins A, Aaron CK. Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. J Toxicol Clin Toxicol. 1996. 34(3):335-41. [QxMD MEDLINE Link].

5. Ourique GM, Pês TS, Saccol EM, Finamor IA, Glanzner WG, Baldisserotto B, et al. Resveratrol prevents oxidative damage and loss of sperm motility induced by long-term treatment with valproic acid in Wistar rats. Exp Toxicol Pathol. 2016 Sep. 68 (8):435-43. [QxMD MEDLINE Link].

6. Ourique GM, Saccol EM, Pês TS, Glanzner WG, Schiefelbein SH, Woehl VM, et al. Protective effect of vitamin E on sperm motility and oxidative stress in valproic acid treated rats. Food Chem Toxicol. 2016 Sep. 95:159-67. [QxMD MEDLINE Link].

7. Li S, Guo J, Ying Z, Chen S, Yang L, Chen K, et al. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology. 2015 May. 61 (5):1730-9. [QxMD MEDLINE Link].

8. Spiller HA, Krenzelok EP, Klein-Schwartz W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol. 2000. 38(7):755-60. [QxMD MEDLINE Link].

9. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila). 2011 Dec. 49 (10):910-41. [QxMD MEDLINE Link]. [Full Text].

10. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Brooks DE, Dibert KW, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila). 2020 Dec. 58 (12):1360-1541. [QxMD MEDLINE Link]. [Full Text].

11. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut. 1984 Jun. 25(6):673-81. [QxMD MEDLINE Link]. [Full Text].

12. Shadnia S, Amiri H, Hassanian-Moghaddam H, Rezai M, Vasei Z, Ghodrati N, et al. Favorable results after conservative management of 316 valproate intoxicated patients. J Res Med Sci. 2015 Jul. 20 (7):656-661. [QxMD MEDLINE Link]. [Full Text].

13. Tank JE, Palmer BF. Simultaneous "in series" hemodialysis and hemoperfusion in the management of valproic acid overdose. Am J Kidney Dis. 1993 Aug. 22(2):341-4. [QxMD MEDLINE Link].

14. Kane SL, Constantiner M, Staubus AE, Meinecke CD, Sedor JR. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother. 2000 Oct. 34(10):1146-51. [QxMD MEDLINE Link].

15. Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry. 2012 May-Jun. 34(3):290-8. [QxMD MEDLINE Link].

16. Caruana Galizia E, Isaacs JD, Cock HR. Non-hyperammonaemic valproate encephalopathy after 20 years of treatment. Epilepsy Behav Case Rep. 2017. 8:9-11. [QxMD MEDLINE Link]. [Full Text].

17. Kay TD, Playford HR, Johnson DW. Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clin Nephrol. 2003 Jan. 59(1):56-8. [QxMD MEDLINE Link].

18. Thanacoody HK. Chronic valproic acid intoxication: reversal by naloxone. Emerg Med J. 2007 Sep. 24(9):677-8. [QxMD MEDLINE Link]. [Full Text].

19. Ishikura H, Matsuo N, Matsubara M, Ishihara T, Takeyama N, Tanaka T. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol. 1996 Jan-Feb. 20(1):55-8. [QxMD MEDLINE Link].

20. LoVecchio F, Shriki J, Samaddar R. L-carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med. 2005 May. 23(3):321-2. [QxMD MEDLINE Link].

21. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007 Apr. 19(2):206-10. [QxMD MEDLINE Link].

22. Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010 Jul-Aug. 44(7-8):1287-93. [QxMD MEDLINE Link].

23. Glatstein M, Bonifacio Rino P, de Pinho S, Scolnik D, Pivko-Levi D, Hoyte C. Levocarnitine for the Treatment of Valproic Acid-Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center. Am J Ther. 2019 May/Jun. 26 (3):e344-e349. [QxMD MEDLINE Link].

24. Dreucean D, Beres K, McNierney-Moore A, Gravino D. Use of meropenem to treat valproic acid overdose. Am J Emerg Med. 2019 Nov. 37 (11):2120.e5-2120.e7. [QxMD MEDLINE Link].

25. Thomas C, Priano J, Smith TL. Meropenem as an antidote for intentional valproic acid overdose. Am J Emerg Med. 2020 Mar. 38 (3):690.e1-690.e2. [QxMD MEDLINE Link].

26. Muñoz-Pichuante D, Villa-Zapata L, Lolas R. Meropenem for management of valproic acid overdose: a case report. Drug Metab Pers Ther. 2020 Jun 30. 35 (2):[QxMD MEDLINE Link].

27. Bigler D. Neurological sequelae after intoxication with sodium valproate. Acta Neurol Scand. 1985 Sep. 72(3):351-2. [QxMD MEDLINE Link].

Asim A Abbasi, MD, FAAP Instructor, Department of Emergency Medicine, Strong Memorial Hospital, University of Rochester School of Medicine and Dentistry

Asim A Abbasi, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Kent R Olson, MD, FACEP Clinical Professor of Medicine and Pharmacy, University of California, San Francisco, School of Medicine; Medical Director, San Francisco Division, California Poison Control System

Kent R Olson, MD, FACEP is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology

Disclosure: Nothing to disclose.

Timothy J Wiegand, MD Director, Ruth A Lawrence Poison and Drug Information Center, Associate Clinical Professor of Medicine and Emergency Medicine, University of Rochester Medical Center and Strong Memorial Hospital

Timothy J Wiegand, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, American College of Physicians

Disclosure: Nothing to disclose.

Michael A Miller, MD Clinical Professor of Emergency Medicine, Medical Toxicologist, Department of Emergency Medicine, Texas A&M Health Sciences Center; CHRISTUS Spohn Emergency Medicine Residency Program

Michael A Miller, MD is a member of the following medical societies: American College of Medical Toxicology

Disclosure: Nothing to disclose.

Fred Harchelroad, MD, FACMT, FAAEM, FACEP Attending Physician in Emergency Medicine, Excela Health System

Disclosure: Nothing to disclose.

Herbert E Hern Jr, MD Assistant Clinical Professor, Department of Emergency Medicine, University of California, San Francisco; Residency Director, Department of Emergency Medicine, Highland General Hospital

Herbert E Hern Jr, MD, is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Lance W Kreplick, MD, FAAEM, MMM Medical Director of Hyperbaric Medicine, Fawcett Wound Management and Hyperbaric Medicine; Consulting Staff in Occupational Health and Rehabilitation, Company Care Occupational Health Services; President and Chief Executive Officer, QED Medical Solutions, LLC

Lance W Kreplick, MD, FAAEM, MMM, is a member of the following medical societies: American Academy of Emergency Medicine and American College of Physician Executives

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Acknowledgments

The staff, faculty, and fellows of the San Francisco Bay Area Regional Poison Control Center contributed insight, review, and encouragement for this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article